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Introduction
Chronic hepatitis C is the leading cause of cirrho-
sis, hepatocellular carcinoma (HCC), and liver trans-
plantation. Therefore a  reduction of hepatitis C virus 
(HCV) prevalence should be a crucial activity for public 
health. According to a recent estimation, about 200 000 
individuals are infected with the HCV in Poland [1]. 
As demonstrated recently, a significant reduction of the 
HCV burden in Poland is possible due to improved di-
agnosis and increased treatment efficacy [2]. 
The new generation of direct acting antivirals 
(DAA) available from 2014 combined with each other 
provide sustained virologic response (SVR) rates above 
90% irrespectively of fibrosis, treatment history or host 
factors that significantly affected the efficacy of the pre-
vious regimens. Moreover, the safety profile in the ma-
jority of patient populations is excellent, and the treat-
ment duration usually does not exceed 12 weeks [3-5]. 
The new Polish reimbursement policy for HCV treat-
ment, which is based on clinical practice guidelines 
of the Polish HCV Expert Group, provides an oppor-
tunity for successful reduction of HCV prevalence [6]. 
The major factor which still affects efficacy of the treat-
ment is HCV genotype (G). Therefore current knowl-
edge on genotype distribution is crucial for further 
development of the therapeutic strategy and reimburse-
ment policy. According to data from 14 651 patients 
treated in Poland between 2003 and 2012, the majority 
were infected with genotype 1 (79%), followed by G3 
(14%) and G4 (5%) [7]. Unfortunately this analysis did 
not include subgenotyping in patients infected with G1 
and did not reflect the most recent epidemiological sit-
uation. 
The aim of this study was to assess current occur-
rence of HCV genotypes in Poland, which can be help-
ful in development of treatment strategies necessary to 
control the HCV infection burden.
Material and methods
Data were collected with an Excel (Microsoft) based 
questionnaire filled out by 29 Polish centers from 15 
voivodships involved in diagnosis and treatment of 
HCV-infected patients. All voivodships, except opol-
skie, were included in the database. The questionnaire 
contained information on number of patients diag-
nosed with each genotype (1a, 1b, 2, 3, 4, 5, 6) in partic-
ular years between 1 January 2013 and 31 March 2016. 
Submitted data were combined and genotypes’ preva-
lence, geographic distribution and annual changes were 
analyzed. 
Results
Data from a  total of 9800 surveyed patients were 
entered into the database. As shown in Table 1, the 
most frequent was genotype 1, identified in 84.9% 
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of patients, followed by G3 (11.3%), G4 (3.5%) and 
G2 (0.2%). Genotypes 5 and 6 were reported in 6 patients 
only (0.1%). Subgenotype 1b was reported in 62.6% of 
patients, which means 73.7% of patients infected with 
G1 (Fig. 1). Since there were no subgenotyping data 
available for 1947 patients, we carried out estimations 
based on data from the subgenotyped population. 
The proportion of G1b among 6374 subgenotyped pa-
tients (G1a + G1b) was 96%, which allowed us to calcu-
late the possible number of 1869 G1b patients among 
those without available subgenotyping. According to 
this calculation, prevalence of G1b can be estimated as 
81.7% and G1a as 3.2%. Data from voivodeships with 
the subgenotyping rate > 95% demonstrate that G1b 
prevalence can vary in particular regions, from 62.9% 
in lubuskie to 89.5% in świętokrzyskie. 
Geographic analysis of major genotypes’ prevalence 
indicates significant regional differences (Table 1). 
The highest prevalence of G1 was observed in central 
(łódzkie, mazowieckie, świętokrzyskie), eastern (lubel-
skie) and southern (małopolskie, śląskie) Poland, where-
as the highest rate of G3 was observed in south-western 
Table 1. Distribution of HCV genotypes in particular voivodeships among patients diagnosed between 1 January 2013 and 31 March 2016 in 29 centers; 
no data available for opolskie voivodeship. Estimations of G1a and G1b prevalence in all G1 patients based on the proportion of subgenotypes among those 
subgenotyped (G1a/G1b: 4/96) are shown in brackets
n Genotypes
1 All 1a 1b 1 Other* 2 3 4 5 6
8321 239 6135 1947 21 1113 339 1 5
Poland 9800 84.9% 2.4% (3.2%) 62.6% (81.7%) 19.9% 0.2% 11.3% 3.5% 0% 0.1%
Voivodeships
podlaskie 184 70.1% 3.3% 66.8% 0% 0.5% 17.4% 11.4% 0% 0.5%
lubuskie 536 72.2% 6.2% 62.9% 3.2% 0.4% 20.5% 6.9% 0% 0%
podkarpackie 137 72.3% 2.2% 69.3% 0.7% 0% 17.5% 10.2% 0% 0%
dolnośląskie 1000 74.7% 1.7% 28.0% 45.0% 0.2% 20.9% 4.2% 0% 0%
warmińsko-mazurskie 202 76.2% 0.5% 51.0% 24.8% 0.5% 16.8% 5.9% 0.5% 0%
kujawsko-pomorskie 523 79.2% 0.4% 14.9% 63.9% 0% 11.7% 8.8% 0% 0.4%
pomorskie 531 80.0% 0.0% 20.3% 59.7% 0.6% 15.3% 4.0% 0% 0.2%
mazowieckie 1428 86.7% 2.7% 79.1% 4.8% 0.2% 9.9% 3.2% 0% 0%
wielkopolskie 426 87.8% 10.1% 70.2% 7.5% 0% 8.7% 3.5% 0% 0%
śląskie 2189 88.8% 1.0% 81.7% 6.1% 0.2% 9.5% 1.6% 0% 0%
zachodniopomorskie 57 89.5% 1.8% 78.9% 8.8% 0% 5.3% 5.3% 0% 0%
świętokrzyskie 380 89.7% 0.3% 89.5% 0% 0% 7.1% 3.2% 0% 0%
małopolskie 918 90.3% 2.0% 81.7% 6.6% 0.2% 7.5% 2.0% 0% 0%
łódzkie 895 92.2% 5.8% 47.9% 38.4% 0.1% 6.4% 1.2% 0% 0.1%
lubelskie 394 92.6% 0.5% 58.4% 33.8% 0.3% 5.1% 2.0% 0% 0%
*Genotype 1 without subgenotyping 
*Genotype 1 without subgenotyping
Fig. 1. Distribution of HCV genotypes in 9800 Polish patients enrolled for 
treatment of chronic hepatitis C between 1 January 2013 and 31 March 2016 
in 29 centers. Estimations of G1a and G1b prevalence in all G1 patients based 
on the proportion of subgenotypes among those subgenotyped (G1a/G1b: 
4/96) are shown in brackets
G2
0.2%
G1*
19.9%
G3
11.3%
G4
3.5%
G5
0.0%
G6
0.1%
G1b
62.6%
(81.7%)
G1a
2.4%
(3.2%)
Clinical and Experimental Hepatology 4/2016
Prevalence of HCV genotypes in Poland
147
(dolnośląskie, lubuskie) and eastern (podlaskie, war-
mińsko-mazurskie, podkarpackie) Poland.
As shown in Figure 2, between 2013 and 2016 
there is an increasing tendency of G1 prevalence from 
84.1% to 87.8%. Irrespective of the increasing propor-
tion of subgenotyped G1 infections (from 55% in 2013 
to 81.7% in 2016), there is a stable, low prevalence of 
G1a (2.5%). However, data from voivodeships with the 
highest prevalence of G1a indicate some regional dif-
ferences. An increasing tendency is observed in pod-
laskie, a  stable or fluctuating tendency in mazowie-
ckie and wielkopolskie, and a decreasing tendency in 
lubuskie and wielkopolskie (Fig. 3). The annual prev-
alence of G3 shows a  decrease from 12.8% in 2013 
to 9.1% in 2016 (Fig. 2), which is supported by data 
from voivodeships with the highest G3 rate (Fig. 4). 
In contrast, the prevalence of G4 is stable (Fig. 2), but 
an increasing tendency in lubuskie and warmińsko- 
mazurskie requires further monitoring (Fig. 5).
Discussion
The current study demonstrated predominance of 
G1b infection among the studied population of pa-
tients diagnosed between 2013 and 2016. The prev-
alence of G1b is estimated at 81.7% followed by G3 
(11.3%), G4 (3.5%) and G1a (3.2%). Other genotypes 
(G2, G5 and G6) were demonstrated in individual cases 
only. The genotype distribution in Poland seems to be 
similar to other Central-European countries. Accord-
ing to recent data, 80-85% of HCV infections in the 
Czech Republic are related to G1b, followed by HCV 
G3 (10-15%) [8]. In Slovakia G1b was identified as 
the most common, followed by genotype 3a and other 
genotypes (including 1a) [8]. In Hungary before 1993, 
among patients infected via blood and blood products, 
genotype 1b almost exclusively dominated, but due to 
the predominance of drug users genotype 1a recently 
became the most prevalent, and the remaining geno-
*Genotype 1 without subgenotyping
Fig. 2. Annual changes in distribution of HCV genotypes between 2013 and 
2016 in Poland
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types are G3 and G1b [8]. Also in Germany the most 
prevalent are G1 and G3 [9]. 
We were able to demonstrate an increase of G1b 
prevalence during the period 2013-2016, which was 
a consequence of both the increase of overall G1 prev-
alence and more frequent subgenotyping for G1. Com-
pared to historical data there is an increasing tendency 
of G1 prevalence from 72.0% in 2003 to 87.5% in 2016, 
which was accompanied by a decrease of G3 (17.9% vs. 
9.1%) and G4 (9.0% vs. 3.1%) [9]. The highest prev-
alence of G1 in central/southern Poland and G3 in 
north-eastern/south-western did not change signifi-
cantly. The most significant increase of G1 prevalence 
compared to previous data was observed in warmiń-
sko-mazurskie (62.0% vs. 76.2%), mazowieckie (76.6% 
vs. 86.7%), lubelskie (82.8% vs. 92.6%), zachodnio-
pomorskie (80.5% vs. 89.5%) and świętokrzyskie 
(81.5% vs. 89.7%). In other voivodeships the propor-
tion of G1 patients among the HCV-infected popula-
tion was at the previous level. A decrease of the pro-
portion of G3 was seen particularly in voivodeships 
with previously demonstrated high prevalence of 
this genotype, which included warmińsko-mazurskie 
(28.1% vs. 16.8%), zachodniopomorskie (16.2% vs. 
5.3%), świętokrzyskie (14.8% vs. 7.1%) and podlaskie 
(23.0% vs. 17.4%). Interestingly, the difference between 
voivodships with the highest versus lowest prevalence 
of G1 decreased from 27.2% in the period 2003-2012 to 
22.5% in 2013-2016, and for G3 from 20.2% to 15.8% 
respectively. This indicates possible obsolescence of re-
gional differences in the future.
The distribution of genotype 3 occurrence may be 
connected with migrations of the twenty century, but 
could also be an effect of single focal outbreaks result-
ing from intravenous drug use and/or nosocomial, 
iatrogenic infections spreading selected HCV variants. 
Clarification could be possible using sequencing tech-
niques in a large number of patients, but will be diffi-
cult in the near future due to the expected successful 
reduction of HCV prevalence in Poland. 
The low prevalence of G1a and G4 seems to be sta-
ble, but in some regions it is higher than average for 
the country and demonstrates annual fluctuations. 
This probably can be explained by local small out-
breaks related to drug use, but it should be investigated 
and clarified at the regional level.
Conclusions
In this study we were able to demonstrate pre-
dominance of genotype 1 (84.9%), which is almost 
exclusively subgenotype 1b, followed by genotypes 3 
(11.3%) and 4 (3.5%). During the last 16 years, prev-
alence of genotype 1 increased from 72% in 2003 to 
87.5% in 2016, and it was accompanied by a decrease 
of genotype 3 and 4 prevalence. Some geographic dif-
ferences in genotype distribution between particular 
regions still exist, but they are smaller than previously. 
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